HaiHe raises $147M in series B to advance cancer candidates

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) raised $146.6 million to advance its oncology focused pipeline in a series B round led by Huagai Capital. Also

Read the full 265 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE